Subscribe (Free) to
Daily or Weekly Newsletters
Post a Job

Featured Jobs

Team Leader

Nova 401(k) Associates
(Remote)

Nova 401(k) Associates logo

Director of Regulatory Operations and Compliance

PCS Retirement
(Remote / PA)

PCS Retirement logo

Retirement Plan Analyst - DC Plans

M2B Retirement Consulting LLC
(Remote / PA)

M2B Retirement Consulting LLC logo

Retirement Plan Administrator

RetirementPlans.com, LLC
(Remote / Addison TX)

RetirementPlans.com, LLC logo

Senior Retirement Plan Analyst - DC Plans

M2B Retirement Consulting LLC
(Remote / PA)

M2B Retirement Consulting LLC logo

Employee Benefits Attorney

Reid & Riege PC
(Hartford CT / Hybrid)

Reid & Riege PC logo

Relationship Manager – MEP/PEP

Benefit Plans Plus
(Remote / Saint Louis MO)

Benefit Plans Plus logo

Relationship Manager

Benefit Plans Plus
(Remote / Saint Louis MO)

Benefit Plans Plus logo

CDHP Consultant

BPAS
(Remote / Houston TX / NY / WA / Hybrid)

BPAS logo

View More Employee Benefits Jobs

Free Newsletters

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Mobile app icon
LinkedIn icon     Twitter icon     Facebook icon
Webinars
and Podcasts
  >  Upcoming   |   On-Demand
Conferences   >  Upcoming   |   Grouped by Location
All Webinars, Podcasts and Conferences   >  Upcoming   |   Grouped by Sponsor

View More Brown & Brown Webinars, Podcasts and Conferences

2025 Employee Benefits Market Trends, Part 2 of 3: Transformative Therapies and PBM Trends

Brown & Brown

Mar. 19, 2025
On-Demand
Podcast

Vanessa, Jared & Adam are joined by Katy Wong, National Pharmacy Leader for Brown & Brown, to discuss the latest trends in transformative therapies and pharmacy benefit management (PBM). Katy highlights how GLP-1s, specialty drugs and gene therapies will continue to drive up costs and how biosimilars are expected to help offset these expenses to health plans. 

The team dives into the challenging landscape facing the traditional PBM model in 2025. Transparency and accountability remain critical for plan sponsors, opening the door for disruptor PBMs and non-traditional PBM delivery models. The team also addresses high-cost drugs in the pipeline, transparency concerns and the current regulatory and legislative dynamics impacting plan sponsors. 

More Information, How to Register